PATENT CLAIM ANALYSIS

Application Number: 16105479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "231500"]

Abstract:
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Claim (Index 79):
The method of  claim 77 , wherein the treating further comprises inducing apoptosis of abnormal bone marrow cells, inducing apoptosis of at least 50% of abnormal bone marrow cells or inducing G1 cell arrest in at least 30% of abnormal bone marrow cells.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 96.0
- Lexical Diversity: 1.21429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15328235', '15816372', '15048389', '14783360', '14408475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7718390761131612
- 35 USC 102 Novelty (BERT): 0.6295071756831152
- Combined Prediction Score: 0.7576058860701566
- Mean Citation Score: 336.052712
- Max Citation Score: 643.62946
- Similarity Product: 505.7088888309324

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test